Methods and compositions for modifying assembly-activating protein (AAP)-dependence of viruses
US-11034732-B2 · Jun 15, 2021 · US
Methods of predicting ancestral virus sequences and uses thereof
US12359174B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12359174-B2 |
| Application number | US-202117408104-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 20, 2021 |
| Priority date | Oct 11, 2013 |
| Publication date | Jul 15, 2025 |
| Grant date | Jul 15, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
First claim
Opening claim text (preview).
What is claimed is: 1. A method comprising: administering to a subject in need thereof a plurality of recombinant adeno-associated virus (rAAV) particles, wherein each rAAV particle comprises an AAV capsid polypeptide and a transgene, wherein the AAV capsid polypeptide comprises an amino acid sequence chosen from: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and the transgene is within the rAAV particle. 2. The method of claim 1 , wherein the method is a method of vaccinating the subject. 3. The method of claim 1 , wherein the method is a method of delivering a gene therapy to the subject. 4. The method of claim 1 , wherein the AAV capsid polypeptide exhibits less seroprevalence than an AAV2 capsid polypeptide and/or about the same or less seroprevalence than an AAV8 capsid polypeptide. 5. The method of claim 1 , wherein the AAV capsid polypeptide is neutralized to a lesser extent by human serum than an AAV2 capsid polypeptide, and wherein the AAV capsid polypeptide is neutralized to a similar or lesser extent by human serum than an AAV8 capsid polypeptide. 6. The method of claim 1 , wherein the AAV capsid polypeptide has the sequence of SEQ ID NO: 1. 7. The method of claim 1 , wherein the subject is a human. 8. The method of claim 1 , wherein the plurality of rAAV particles are in a composition further comprising a carrier. 9. The method of claim 1 , wherein the plurality of rAAV particles transduces or infects cells in the subject. 10. The method of claim 9 , wherein the cells are ear cells. 11. The method of claim 10 , wherein the ear cells are inner ear cells. 12. The method of claim 4 , wherein the subject has a lower titer of antibodies that are capable of neutralizing the AAV capsid polypeptide than the titer of antibodies capable of neutralizing an AAV2 or AAV8 capsid polypeptide.
Assignees
Inventors
Classifications
Virus like particles [VLP] · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
against growth factors {; against growth regulators} · CPC title
virus or viral particle as vehicle, e.g. encapsulating small organic molecule · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12359174B2 cover?
- Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
- Who is the assignee on this patent?
- Massachusetts Eye & Ear Infirmary, Schepens Eye Res Inst
- What technology area does this patent fall under?
- Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).